PhoreMost Advances Cancer Treatment with $50M Funding Boost
PhoreMost, a biopharmaceutical leader, has secured an additional $12 million in Series B financing, raising its total to over $50 million.This funding boost, led by Parkwalk Advisors, supports its mission…




